Trevi Therapeutics Inc.(TRVI)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TRVI Trevi Therapeutics Inc.

休市中 02-27 16:00:00 EST

11.92

+0.40

+3.47%

盘后11.92

+0.000.00%

17:59 EST

最高11.95	最低11.31	成交量130.51万
今开11.36	昨收11.52	日振幅5.60%
总市值15.29亿	流通市值11.57亿	总股本1.28亿
成交额1,539万	换手率1.34%	流通股本9,709万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TRVI","market":"US","secType":"STK","nameCN":"Trevi Therapeutics Inc.","latestPrice":11.92,"timestamp":1772226000000,"preClose":11.52,"halted":0,"volume":1305070,"hourTrading":{"tag":"盘后","latestPrice":11.92,"preClose":11.92,"latestTime":"17:59 EST","volume":66674,"amount":794749.7431,"timestamp":1772233171926,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03472222222222225,"floatShares":97087500,"shares":128230134,"eps":-0.367299,"marketStatus":"休市中","change":0.4,"latestTime":"02-27 16:00:00 EST","open":11.36,"high":11.95,"low":11.305,"amount":15388864.71707,"amplitude":0.05599,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.367299,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1557201600000,"exchange":"NASDAQ","adjPreClose":11.52,"preHourTrading":{"tag":"盘前","latestPrice":11.34,"preClose":11.52,"latestTime":"09:29 EST","volume":105,"amount":1191.5499750000001,"timestamp":1772202599999,"change":-0.18,"changeRate":-0.015625,"amplitude":0.014757},"postHourTrading":{"tag":"盘后","latestPrice":11.92,"preClose":11.92,"latestTime":"17:59 EST","volume":66674,"amount":794749.7431,"timestamp":1772233171926,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.165718774452236,"impliedVol":0.3743,"impliedVolPercentile":0.2072},"requestUrl":"/m/hq/s/TRVI","defaultTab":"news","newsList":[{"id":"1126825574","title":"Trevi Therapeutics宣布Nalbuphine ER治疗特发性肺纤维化慢性咳嗽的IIb期试验数据发表于《美国医学会杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1126825574","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126825574?lang=zh_cn&edition=full","pubTime":"2026-01-23 01:30","pubTimestamp":1769103015,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics公司近日宣布，其针对特发性肺纤维化（IPF）相关慢性咳嗽的Nalbuphine ER缓释片IIb期临床试验数据，已正式发表于国际权威医学期刊《美国医学会杂志》（JAMA）。\n该试验旨在评估Nalbuphine ER在缓解IPF患者慢性咳嗽症状方面的有效性与安全性。研究结果的公开发表，为这一潜在疗法的临床价值提供了重要的学术支持。\n数据的发布标志着Trevi Therapeutics在呼吸系统疾病治疗领域取得了阶段性进展，也为后续临床开发奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"gpt_icon":0},{"id":"1117780818","title":"Trevi Therapeutics在摩根大通医疗健康年会期间举办的企业交流活动前公布战略动向","url":"https://stock-news.laohu8.com/highlight/detail?id=1117780818","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117780818?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:32","pubTimestamp":1767875527,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics公司于近期披露了关键战略更新，此举恰逢在摩根大通医疗健康年会期间举行的年度LifeSci Partners企业交流活动前夕。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235295.USD","LU0149725797.USD","BK4585","LU1551013342.USD","LU1496350171.SGD","LU2211815571.USD","IE00BJTD4N35.SGD","BK4007","LU2462157665.USD","LU0106831901.USD","LU0820561909.HKD","LU1988902786.USD","LU1720051017.SGD","IE00BFXG1179.USD","LU0943347566.SGD","LU1629891620.HKD","BK4207","LU0048584097.USD","LU0496365809.HKD","LU0683600562.USD","LU2237443465.HKD","LU2756315318.SGD","IE0034235188.USD","BK4504","LU0211326755.USD","IE00BHPRN162.USD","LU1116320901.HKD","LU2430703095.HKD","LU2505996509.AUD","BK4581","LU2237443895.HKD","LU0882574139.USD","LU0320765646.SGD","IE00BKDWB100.SGD","LU0106261372.USD","LU1670628061.USD","LU0323591593.USD","LU0820561818.USD","BK4588","LU0787776722.HKD","LU1496350502.SGD","LU1119994496.HKD","LU2237443978.SGD","LU0345770993.USD","LU1084165304.USD","LU0006306889.USD","LU1032466523.USD","LU2592432038.USD","BK4534","LU0208291251.USD","LU1162221912.USD","LU0640476718.USD","BK4550","LU2552382132.HKD","LU0345769631.USD","LU1145028129.USD","LU2237443622.USD","LU1244550221.USD","LU2023250504.SGD","LU0203345920.USD","IE00BDCRKT87.USD","LU2106854487.HKD","LU1548497426.USD","IE000M9KFDE8.USD","LU0310799852.SGD","LU1244550577.SGD","LU1668664300.SGD","LU2417539215.USD","LU2357305700.SGD","IE00BJTD4V19.USD","LU0689472784.USD","LU0211327993.USD","LU0251132253.USD","LU0345770308.USD","IE00B1XK9C88.USD","LU2756315664.SGD","LU0320765489.SGD","BK4516","IE00BWXC8680.SGD","LU1974910355.USD","LU2430703178.SGD","LU1914381329.SGD","LU2023250843.SGD","LU2552382058.USD","LU1064131342.USD","SG9999002224.SGD","SG9999002232.USD","LU2236285917.USD","LU2381873111.SGD","IE00BLSP4452.SGD","LU0868494617.USD","TRVI","LU0203347892.USD","IE00BN8TJ469.HKD","LU2456880835.USD","LU1267930490.SGD","LU1116320737.USD","IE00BZ1G4Q59.USD","LU0234572021.USD","LU0942090050.USD","LU1261432733.SGD","LU1363072403.SGD","IE00BYXW3230.USD","LU1551013425.SGD","LU1280957306.USD","LU0265550359.USD","LU0267386448.USD","LU1917777945.USD","IE00BKVL7J92.USD","LU1670627923.USD","LU0070302665.USD","LU2746668974.SGD","LU2054465674.USD","LU2505996681.GBP","LU0170899867.USD","LU2264538146.SGD","LU0971096721.USD","LU0215105999.USD","BK4533","LU0964807845.USD","IE00B3S45H60.SGD","IE00BDRTCR15.USD","LU2430703251.USD","IE00BBT3K403.USD","LU1894683264.USD","LU0265550946.USD","LU0256863811.USD","LU2213496289.HKD","LU2746668461.USD","LU1244550494.USD","LU0976567544.SGD","IE00BLSP4239.USD","LU2552382215.SGD","LU1720051108.HKD","LU1366192091.USD","IE0034235303.USD","IE00B1BXHZ80.USD","IE00B775SV38.USD","LU0211326839.USD","LU0211328371.USD","IE00BJLML261.HKD","LU2023250330.USD","LU2237443382.USD","LU2242649171.HKD","LU0345769128.USD","LU0820562030.AUD","LU0868494708.USD","BK4566","LU1894683348.USD","LU2237443549.SGD","LU0238689110.USD","LU0417517546.SGD","LU0211331839.USD"],"gpt_icon":0},{"id":"1107382272","title":"Trevi Therapeutics 第三季度净收入为-1180.2万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107382272","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107382272?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:47","pubTimestamp":1763574436,"startTime":"0","endTime":"0","summary":"11月13日讯 - Trevi Therapeutics第三季度运营费用为1391.6万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"gpt_icon":0},{"id":"2569375852","title":"Trevi Therapeutics, Inc.盘中异动 下午盘股价大涨5.03%报8.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569375852","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569375852?lang=zh_cn&edition=full","pubTime":"2025-09-23 02:47","pubTimestamp":1758566842,"startTime":"0","endTime":"0","summary":"北京时间2025年09月23日02时47分，Trevi Therapeutics, Inc.股票出现波动，股价快速拉升5.03%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.95%。其相关个股中，Qualigen Therapeutics, Inc.、Mbx Biosciences, Inc.、Metsera, Inc.涨幅较大，Qualigen Therapeutics, Inc.、Onconetix, Inc.、Mbx Biosciences, Inc.较为活跃，换手率分别为3441.04%、161.31%、74.26%，振幅较大的相关个股有Qualigen Therapeutics, Inc.、Mbx Biosciences, Inc.、Kodiak Sciences Inc，振幅分别为144.19%、86.84%、63.32%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923024723a72fe46a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923024723a72fe46a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","TRVI","BK4007","BK4139"],"gpt_icon":0},{"id":"2567190639","title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","url":"https://stock-news.laohu8.com/highlight/detail?id=2567190639","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567190639?lang=zh_cn&edition=full","pubTime":"2025-09-13 06:38","pubTimestamp":1757716705,"startTime":"0","endTime":"0","summary":"研发新冠疫苗的BioNTech盘中跌超10%、莫德纳跌超7%、Novavax跌超4%。投资者担心，如果特朗普政府进一步收紧疫苗接种政策，可能对疫苗制造商的业务造成重大冲击，特别是对莫德纳这类高度依赖新冠疫苗收入的公司。更新中","market":"us","thumbnail":"https://static.tigerbbs.com/632b4e916ff966270173f4303843021f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/632b4e916ff966270173f4303843021f"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3755508","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"ae8bc75ba4d1918dcafc0476d86c6d53","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3755508","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"生物科技股集体重挫！报道称特朗普政府将儿童死亡甩锅新冠疫苗接种","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BMY","BNTX","TARS","AZN","ARCT","TRVI","STRO","KALV","PSNL","NVS","TVTX","BK4009","NVAX","SRPT","MRK","MRNA","PFE","ABUS","PGEN"],"gpt_icon":1},{"id":"2518205376","title":"HC Wainwright & Co.：维持Trevi Therapeutics(TRVI.US)评级，由买入调整至买入评级, 目标价由7.50美元调整至12.50美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518205376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518205376?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:41","pubTimestamp":1741628499,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Trevi Therapeutics(TRVI.US)评级，由买入调整至买入评级, 目标价由7.50美元调整至12.50美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11014148641576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TRVI","LENZ"],"gpt_icon":0},{"id":"2518275991","title":"Trevi Therapeutics, Inc.盘中异动 早盘急速上涨53.49%报6.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518275991","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518275991?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:30","pubTimestamp":1741613405,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时30分，Trevi Therapeutics, Inc.股票出现异动，股价大幅拉升53.49%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213005a26a23d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213005a26a23d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","TRVI"],"gpt_icon":0},{"id":"2516666876","title":"Trevi Therapeutics, Inc.盘中异动 急速下挫5.09%报4.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516666876?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:14","pubTimestamp":1741032851,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时14分，Trevi Therapeutics, Inc.股票出现波动，股价快速跳水5.09%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041412abe69252&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041412abe69252&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TRVI","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2514378194","title":"Trevi Therapeutics, Inc.盘中异动 股价大跌7.33%报4.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514378194?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753062,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Trevi Therapeutics, Inc.股票出现异动，股价急速下挫7.33%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502282231029896796a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502282231029896796a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TRVI","BK4007","LENZ"],"gpt_icon":0},{"id":"2514389009","title":"Trevi Therapeutics, Inc.盘中异动 股价大涨5.10%报4.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514389009?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:20","pubTimestamp":1740669609,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时20分，Trevi Therapeutics, Inc.股票出现异动，股价急速上涨5.10%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.94%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232009abdf7bad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232009abdf7bad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","TRVI"],"gpt_icon":0},{"id":"2514041811","title":"Trevi Therapeutics, Inc.盘中异动 快速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514041811","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514041811?lang=zh_cn&edition=full","pubTime":"2025-02-26 04:58","pubTimestamp":1740517139,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日04时58分，Trevi Therapeutics, Inc.股票出现波动，股价急速上涨5.10%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045859abdcd5f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226045859abdcd5f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","TRVI"],"gpt_icon":0},{"id":"2514702770","title":"Trevi Therapeutics, Inc.盘中异动 下午盘大幅下挫5.54%报4.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514702770","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514702770?lang=zh_cn&edition=full","pubTime":"2025-02-25 03:29","pubTimestamp":1740425356,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日03时29分，Trevi Therapeutics, Inc.股票出现异动，股价快速跳水5.54%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.37%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225032917962ed3f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225032917962ed3f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TRVI","BK4007"],"gpt_icon":0},{"id":"2513729972","title":"Trevi Therapeutics, Inc.盘中异动 股价大涨5.21%报5.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513729972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513729972?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:30","pubTimestamp":1740148229,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时30分，Trevi Therapeutics, Inc.股票出现异动，股价快速上涨5.21%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223030988dddc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223030988dddc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TRVI","BK4007"],"gpt_icon":0},{"id":"2512435232","title":"Trevi Therapeutics, Inc.盘中异动 快速上涨5.09%报4.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512435232","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512435232?lang=zh_cn&edition=full","pubTime":"2025-02-20 03:19","pubTimestamp":1739992789,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日03时19分，Trevi Therapeutics, Inc.股票出现波动，股价快速上涨5.09%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.58%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220031949abd53208&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220031949abd53208&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TRVI","BK4007"],"gpt_icon":0},{"id":"2512193256","title":"Trevi Therapeutics, Inc.盘中异动 急速拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512193256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512193256?lang=zh_cn&edition=full","pubTime":"2025-02-19 02:06","pubTimestamp":1739902005,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日02时06分，Trevi Therapeutics, Inc.股票出现波动，股价快速拉升5.04%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219020646988a201e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219020646988a201e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","TRVI","LENZ"],"gpt_icon":0},{"id":"2510336829","title":"Trevi Therapeutics, Inc.盘中异动 早盘快速下挫5.05%报3.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510336829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510336829?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:19","pubTimestamp":1739287180,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时19分，Trevi Therapeutics, Inc.股票出现波动，股价大幅跳水5.05%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.60%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211231940961f5137&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211231940961f5137&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","TRVI","BK4007"],"gpt_icon":0},{"id":"2510186646","title":"Trevi Therapeutics, Inc.盘中异动 早盘快速下挫5.42%报4.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510186646","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510186646?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:55","pubTimestamp":1739199338,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时55分，Trevi Therapeutics, Inc.股票出现波动，股价快速下跌5.42%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.18%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210225538abc9ab54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210225538abc9ab54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TRVI","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2508128042","title":"Trevi Therapeutics, Inc.盘中异动 早盘股价大涨5.08%报4.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508128042","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508128042?lang=zh_cn&edition=full","pubTime":"2025-02-04 00:10","pubTimestamp":1738599025,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日00时10分，Trevi Therapeutics, Inc.股票出现异动，股价快速拉升5.08%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.74%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204001026a2381e05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204001026a2381e05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4139","TRVI"],"gpt_icon":0},{"id":"2505042711","title":"Trevi Therapeutics, Inc.盘中异动 快速拉升5.03%报3.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505042711","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505042711?lang=zh_cn&edition=full","pubTime":"2025-01-24 02:44","pubTimestamp":1737657851,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日02时44分，Trevi Therapeutics, Inc.股票出现波动，股价快速拉升5.03%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.06%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124024411abb62c30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124024411abb62c30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TRVI","BK4007","LENZ"],"gpt_icon":0},{"id":"2505795697","title":"Trevi Therapeutics, Inc.盘中异动 大幅拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505795697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505795697?lang=zh_cn&edition=full","pubTime":"2025-01-23 01:32","pubTimestamp":1737567134,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日01时32分，Trevi Therapeutics, Inc.股票出现波动，股价快速拉升5.07%。Trevi Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。Trevi Therapeutics, Inc.公司简介：Trevi Therapeutics Inc 是一家临床阶段的生物制药公司，专注于研究疗法 Haduvio的开发和商业化，用于治疗患有特发性肺纤维化或 IPF 的成人慢性咳嗽和其他慢性咳嗽适应症，以及用于 结节性痒疹的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123013214986f9472&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123013214986f9472&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","TRVI","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trevitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1203},{"period":"1month","weight":0.1342},{"period":"3month","weight":-0.0963},{"period":"6month","weight":0.643},{"period":"1year","weight":1.6489},{"period":"ytd","weight":-0.0479}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Trevi Therapeutics, Inc.于2011年3月17日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于开发和商业化纳布啡ER，以治疗严重的神经介导的疾病。该公司目前正在开发纳布啡ER，用于治疗患有特发性肺纤维化或IPF的慢性瘙痒，慢性咳嗽，以及帕金森病患者的左旋多巴诱导的运动障碍或LID。这些病症具有共同的病理生理学，其通过中枢和外周神经系统中的阿片受体介导。由于纳布啡作为阿片受体调节剂的作用机制，该公司认为这有可能有效治疗这些疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.062028},{"month":2,"riseRate":0.857143,"avgChangeRate":0.194268},{"month":3,"riseRate":0.5,"avgChangeRate":0.396594},{"month":4,"riseRate":0.5,"avgChangeRate":0.125322},{"month":5,"riseRate":0,"avgChangeRate":-0.128619},{"month":6,"riseRate":0.714286,"avgChangeRate":0.210852},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.013323},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.078417},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065787},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.063981},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.046063},{"month":12,"riseRate":0.571429,"avgChangeRate":0.034671}],"exchange":"NASDAQ","name":"Trevi Therapeutics Inc.","nameEN":"Trevi Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Trevi Therapeutics Inc.(TRVI)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Trevi Therapeutics Inc.(TRVI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Trevi Therapeutics Inc.,TRVI,Trevi Therapeutics Inc.股票,Trevi Therapeutics Inc.股票老虎,Trevi Therapeutics Inc.股票老虎国际,Trevi Therapeutics Inc.行情,Trevi Therapeutics Inc.股票行情,Trevi Therapeutics Inc.股价,Trevi Therapeutics Inc.股市,Trevi Therapeutics Inc.股票价格,Trevi Therapeutics Inc.股票交易,Trevi Therapeutics Inc.股票购买,Trevi Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Trevi Therapeutics Inc.(TRVI)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Trevi Therapeutics Inc.(TRVI)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}